Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:IOVA NASDAQ:OCS NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$3.89+4.3%$2.99$1.20▼$3.90$221.48M3.071.05 million shs883,960 shsIOVAIovance Biotherapeutics$2.34+4.0%$2.38$1.64▼$12.51$814.17M0.839.93 million shs8.73 million shsOCSOculis$17.57+0.6%$17.50$12.48▼$23.08$762.78M0.2923,018 shs20,345 shsVIRVir Biotechnology$5.73+1.2%$4.99$4.16▼$14.45$786.27M1.271.11 million shs1.75 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics+4.29%+14.41%+35.07%+50.78%-2.38%IOVAIovance Biotherapeutics+4.00%+10.90%+5.88%+33.41%-76.02%OCSOculis+0.57%-0.34%+7.40%-7.31%+43.55%VIRVir Biotechnology+1.24%+4.37%+3.99%+4.37%-25.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$3.89+4.3%$2.99$1.20▼$3.90$221.48M3.071.05 million shs883,960 shsIOVAIovance Biotherapeutics$2.34+4.0%$2.38$1.64▼$12.51$814.17M0.839.93 million shs8.73 million shsOCSOculis$17.57+0.6%$17.50$12.48▼$23.08$762.78M0.2923,018 shs20,345 shsVIRVir Biotechnology$5.73+1.2%$4.99$4.16▼$14.45$786.27M1.271.11 million shs1.75 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics+4.29%+14.41%+35.07%+50.78%-2.38%IOVAIovance Biotherapeutics+4.00%+10.90%+5.88%+33.41%-76.02%OCSOculis+0.57%-0.34%+7.40%-7.31%+43.55%VIRVir Biotechnology+1.24%+4.37%+3.99%+4.37%-25.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.86Moderate Buy$11.00182.78% UpsideIOVAIovance Biotherapeutics 2.27Hold$11.90408.55% UpsideOCSOculis 2.60Moderate Buy$35.75103.47% UpsideVIRVir Biotechnology 2.73Moderate Buy$17.30201.92% UpsideCurrent Analyst Ratings BreakdownLatest BDTX, OCS, IOVA, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025BDTXBlack Diamond TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025IOVAIovance BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025OCSOculisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025VIRVir BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/15/2025VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.009/3/2025BDTXBlack Diamond TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.009/3/2025BDTXBlack Diamond TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.009/3/2025VIRVir BiotechnologyEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$12.008/27/2025OCSOculisNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.008/27/2025VIRVir BiotechnologyBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$12.00 ➝ $14.008/22/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $33.00(Data available from 10/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M3.16N/AN/A$1.47 per share2.65IOVAIovance Biotherapeutics$241.53M3.51N/AN/A$2.33 per share1.00OCSOculis$780K983.47N/AN/A$1.91 per share9.20VIRVir Biotechnology$74.21M10.73N/AN/A$8.35 per share0.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics-$69.68M$0.2316.91N/AN/AN/A12.70%9.58%11/4/2025 (Estimated)IOVAIovance Biotherapeutics-$372.18M-$1.23N/AN/AN/A-161.44%-52.87%-41.31%11/6/2025 (Estimated)OCSOculis-$97.43M-$2.67N/AN/AN/A-13,958.12%-90.31%-67.85%11/6/2025 (Estimated)VIRVir Biotechnology-$521.96M-$4.00N/AN/AN/A-2,895.94%-50.22%-40.78%10/30/2025 (Estimated)Latest BDTX, OCS, IOVA, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025VIRVir Biotechnology-$0.70N/AN/AN/A$1.98 millionN/A8/21/2025Q2 2025OCSOculis-$0.53-$0.59-$0.06-$0.59$0.14 million$0.25 million8/7/2025Q2 2025BDTXBlack Diamond Therapeutics-$0.25-$0.19+$0.06-$0.19N/AN/A8/7/2025Q2 2025IOVAIovance Biotherapeutics-$0.29-$0.33-$0.04-$0.33$67.14 million$59.95 million8/6/2025Q2 2025VIRVir Biotechnology-$0.72-$0.80-$0.08-$0.80$2.38 million$1.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.738.73IOVAIovance BiotherapeuticsN/A3.272.89OCSOculis0.014.554.55VIRVir BiotechnologyN/A7.017.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%IOVAIovance Biotherapeutics77.03%OCSOculis22.30%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics5.97%IOVAIovance Biotherapeutics10.30%OCSOculisN/AVIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9056.94 million53.54 millionOptionableIOVAIovance Biotherapeutics500361.85 million324.58 millionOptionableOCSOculis243.66 millionN/ANot OptionableVIRVir Biotechnology580138.92 million116.69 millionOptionableBDTX, OCS, IOVA, and VIR HeadlinesRecent News About These CompaniesVir Biotechnology (NASDAQ:VIR) Director Sells $128,480.00 in StockOctober 3 at 5:56 AM | insidertrades.comVicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) StockOctober 2 at 12:41 PM | marketbeat.comBrokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $17.30September 25, 2025 | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 20, 2025 | marketbeat.comVir Biotechnology, Inc. $VIR Shares Bought by Goldman Sachs Group Inc.September 17, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Down 4.7% - What's Next?September 16, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR)September 16, 2025 | marketbeat.comVir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 16, 2025 | seekingalpha.com84,398 Shares in Vir Biotechnology, Inc. $VIR Purchased by Cinctive Capital Management LPSeptember 8, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading Down 6% on Insider SellingSeptember 6, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Stock Price Up 8% - Here's WhySeptember 5, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Now Covered by Evercore ISISeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases 185,933 Shares of Vir Biotechnology, Inc. $VIRSeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Sells 542,000 Shares of Vir Biotechnology, Inc. $VIRSeptember 4, 2025 | marketbeat.comEvercore ISI Group Initiates Coverage of Vir Biotechnology (VIR) with Outperform RecommendationSeptember 3, 2025 | msn.comThe Play On Vir BiotechnologySeptember 3, 2025 | seekingalpha.comVir Biotechnology initiated with an Outperform at Evercore ISISeptember 3, 2025 | msn.comVir Biotechnology stock soars after BofA upgrade, $14 targetAugust 28, 2025 | investing.comVir Stock Soars After BofA Boosts Rating on Liver TherapyAugust 28, 2025 | finance.yahoo.comVir upgraded at BoA on potential for liver disease asset; shares surge 13%August 28, 2025 | msn.comMicron initiated, Eli Lilly upgraded: Wall Street's top analyst callsAugust 27, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDTX, OCS, IOVA, and VIR Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$3.89 +0.16 (+4.29%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$3.89 0.00 (0.00%) As of 10/3/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Iovance Biotherapeutics NASDAQ:IOVA$2.34 +0.09 (+4.00%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$2.34 0.00 (0.00%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Oculis NASDAQ:OCS$17.57 +0.10 (+0.57%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$17.55 -0.02 (-0.11%) As of 10/3/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Vir Biotechnology NASDAQ:VIR$5.73 +0.07 (+1.24%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.75 +0.02 (+0.35%) As of 10/3/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding Why GlobalFoundries Just Became a Geopolitical Power Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
